ReviewFrontiers in cell and developmental biology2026
Emerging regulated cell death (cuproptosis, disulfidptosis, and PANoptosis) in ischemic stroke: research progress and translational prospects.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic stroke (IS) is one of the leading causes of disability and mortality worldwide. Its pathological mechanisms involve complex cascades including energy metabolism failure, excitotoxicity, oxidative stress, neuroinflammation, and multiple forms of regulated cell death (RCD). In recent years, cuproptosis, disulfidptosis, and PANoptosis, as three emerging RCD modalities, have attracted increasing attention in ischemic brain injury. Cuproptosis is triggered by copper overload and leads to proteotoxic stress via abnormal oligomerization of lipoylated mitochondrial proteins. Disulfidptosis occurs under glucose deprivation combined with high SLC7A11 expression, driven by NADPH depletion and intracellular disulfide stress that collapses the actin cytoskeleton. PANoptosis integrates pyroptosis, apoptosis, and necroptosis through the PANoptosome-a multiprotein platform assembled by innate immune sensors (ZBP1, AIM2, NLRP3) together with adaptor proteins (ASC, FADD) and effectors (caspase-1/8, RIPK3, MLKL, GSDMD)-leading to simultaneous execution of all three death programs and amplified neuroinflammatory injury. These three death modalities exhibit marked cell-type heterogeneity across neurons, microglia, astrocytes, and endothelial cells within the neurovascular unit, and converge on shared hubs of oxidative stress, mitochondrial dysfunction, and inflammatory signaling, forming a complex inter-pathway crosstalk network. This review systematically summarizes the molecular mechanisms, cellular specificity, spatiotemporal dynamics, and inter-pathway crosstalk of these three emerging RCDs in ischemic stroke, and discusses the clinical translational prospects of targeted and combination intervention strategies-including a stage-classified analysis of therapeutic candidates from preclinical to clinical development-providing a theoretical basis for the design of novel neuroprotective agents.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.